Bruker Swings to Q2 Loss on $135M Goodwill Impairment; Revenue Up 5%
BRKR sits 84% above its 52-week low of $28.53 on elevated volume (1.8× avg).
Summary
Bruker Corporation posted a Q2 2026 net loss of $52.0M after a $134.9M goodwill impairment, overshadowing 5.2% revenue growth. A segment reorganization was also announced.
Key Events · Earnings and Guidance · BRKR
-
$134.9M Goodwill Impairment Drives Q2 Loss
Bruker recorded a $134.9M goodwill impairment charge — $36.5M in BSI NANO (Bruker Spatial Biology) and $98.4M in BSI BioSpin (Chemspeed Technologies) — leading to a net loss of $52.0M attributable to Bruker Corporation.
-
Revenue Up 5.2%, Organic Growth at 2.8%
Total revenue reached $838.5M, up 5.2% year-over-year. Non-GAAP organic revenue grew 2.8%, driven by biotech/pharma and semiconductor markets, partially offset by academic and government weakness.
-
Segment Reorganization Announced
Effective Q3 2026, Bruker will reorganize into four new segments: BSI Biosystems, BSI Microbiology and Infection Diagnostics, BSI NANO, and BEST, aiming to streamline operations and improve accountability.
-
Cash Declines to $184.9M
Cash and cash equivalents fell to $184.9M from $298.8M at year-end 2025, driven by debt repayments, legal settlements, and negative free cash flow, though $729M remains available under the revolving credit facility.
Analysis · BRKR · Industrial Applications And Services
Bruker reported a net loss of $52.0 million for Q2 2026, driven by a $134.9 million goodwill impairment charge split between its BSI NANO and BSI BioSpin segments. The impairment reflects reduced expectations for the Bruker Spatial Biology and Chemspeed Technologies businesses. Revenue grew 5.2% to $838.5 million, with non-GAAP organic growth of 2.8%, but the bottom line was crushed by the non-cash charge. The company also announced a post-quarter segment reorganization, signaling a strategic reset. Cash declined to $184.9 million from $298.8 million at year-end, though the company maintains ample liquidity. The results follow a bruising Q1 and a recent FY26 guidance that missed consensus, reinforcing a challenging turnaround narrative.
At the time of this filing, BRKR was trading at $52.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8B. The 52-week trading range was $28.53 to $65.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.